Protalix BioTherapeutics
PLX
PLX
34 hedge funds and large institutions have $32.9M invested in Protalix BioTherapeutics in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less call options, than puts
Call options by funds: $ | Put options by funds: $
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
42% less capital invested
Capital invested by funds: $56.7M → $32.9M (-$23.9M)
Holders
34
Holding in Top 10
–
Calls
$41K
Puts
$61K
Top Buyers
| 1 | +$26.2K | |
| 2 | +$23.9K | |
| 3 | +$16.3K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15K |
| 5 |
Goldman Sachs
New York
|
+$15K |
Top Sellers
| 1 | -$1.12M | |
| 2 | -$94.7K | |
| 3 | -$78K | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$73.7K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$68K |